中华肝胆外科杂志
中華肝膽外科雜誌
중화간담외과잡지
CHINESE JOURNAL OF HEPATOBILIARY SURGERY
2013年
10期
742-745
,共4页
李涛%樊嘉%钦伦秀%周俭%胡三元%智绪亭%汤钊猷
李濤%樊嘉%欽倫秀%週儉%鬍三元%智緒亭%湯釗猷
리도%번가%흠륜수%주검%호삼원%지서정%탕쇠유
肝脏%透明细胞癌%复发%治疗%预后
肝髒%透明細胞癌%複髮%治療%預後
간장%투명세포암%복발%치료%예후
Liver%Clear cell carcinoma%Recurrence%Therapy%Prognosis
目的 探讨透明细胞型肝癌(PCCCL)术后复发的治疗措施及预后.方法 对1996年1月至2006年3月采用根治性手术切除治疗的214例PCCCL患者的临床及随访资料进行回顾性分析.术后1年及1年以内复发者定义为早期复发,术后1年以上复发者定义为晚期复发.结果 99例PCCCL患者术后复发,其中早期复发者28例,晚期复发者71例.复发患者手术切除33例,酒精注射治疗7例,射频消融治疗10例,动脉化疗栓塞治疗27例,全身化疗和中医治疗各1例,未行治疗20例.晚期复发患者再次手术切除率显著高于早期复发患者(P=0.04).复发患者接受根治性治疗后1年、3年及5年的总生存率分别为100%、86.0%、63.5%,与未复发患者比较(分别为85.2%、72.2%、64.3%),无显著差异(P=0.71).手术切除、射频消融及酒精注射治疗对复发患者生存率的影响无显著差异(P=0.68),均显著优于动脉化疗栓塞(P=0.03).复发患者接受动脉化疗栓塞术后1年、3年及5年的总生存率(分别为100%、66.7%、44.4%)显著优于未栓塞治疗的复发患者(分别为80.0%、25.0%、10.0%,P<0.01).结论 手术切除、射频消融及酒精注射治疗是PCCCL术后复发最佳治疗手段.动脉化疗栓塞对于不能手术切除的复发患者仍能有效延长生存时间.
目的 探討透明細胞型肝癌(PCCCL)術後複髮的治療措施及預後.方法 對1996年1月至2006年3月採用根治性手術切除治療的214例PCCCL患者的臨床及隨訪資料進行迴顧性分析.術後1年及1年以內複髮者定義為早期複髮,術後1年以上複髮者定義為晚期複髮.結果 99例PCCCL患者術後複髮,其中早期複髮者28例,晚期複髮者71例.複髮患者手術切除33例,酒精註射治療7例,射頻消融治療10例,動脈化療栓塞治療27例,全身化療和中醫治療各1例,未行治療20例.晚期複髮患者再次手術切除率顯著高于早期複髮患者(P=0.04).複髮患者接受根治性治療後1年、3年及5年的總生存率分彆為100%、86.0%、63.5%,與未複髮患者比較(分彆為85.2%、72.2%、64.3%),無顯著差異(P=0.71).手術切除、射頻消融及酒精註射治療對複髮患者生存率的影響無顯著差異(P=0.68),均顯著優于動脈化療栓塞(P=0.03).複髮患者接受動脈化療栓塞術後1年、3年及5年的總生存率(分彆為100%、66.7%、44.4%)顯著優于未栓塞治療的複髮患者(分彆為80.0%、25.0%、10.0%,P<0.01).結論 手術切除、射頻消融及酒精註射治療是PCCCL術後複髮最佳治療手段.動脈化療栓塞對于不能手術切除的複髮患者仍能有效延長生存時間.
목적 탐토투명세포형간암(PCCCL)술후복발적치료조시급예후.방법 대1996년1월지2006년3월채용근치성수술절제치료적214례PCCCL환자적림상급수방자료진행회고성분석.술후1년급1년이내복발자정의위조기복발,술후1년이상복발자정의위만기복발.결과 99례PCCCL환자술후복발,기중조기복발자28례,만기복발자71례.복발환자수술절제33례,주정주사치료7례,사빈소융치료10례,동맥화료전새치료27례,전신화료화중의치료각1례,미행치료20례.만기복발환자재차수술절제솔현저고우조기복발환자(P=0.04).복발환자접수근치성치료후1년、3년급5년적총생존솔분별위100%、86.0%、63.5%,여미복발환자비교(분별위85.2%、72.2%、64.3%),무현저차이(P=0.71).수술절제、사빈소융급주정주사치료대복발환자생존솔적영향무현저차이(P=0.68),균현저우우동맥화료전새(P=0.03).복발환자접수동맥화료전새술후1년、3년급5년적총생존솔(분별위100%、66.7%、44.4%)현저우우미전새치료적복발환자(분별위80.0%、25.0%、10.0%,P<0.01).결론 수술절제、사빈소융급주정주사치료시PCCCL술후복발최가치료수단.동맥화료전새대우불능수술절제적복발환자잉능유효연장생존시간.
Objective To evaluate the prognosis and management of recurrent primary clear cell carcinoma of liver (PCCCL).Methods 214 patients with PCCCL treated by curative resection from January 1996 to March 2006 were retrospectively studied.Tumour recurrences were classified into early (≤1 year) and late (>1 year) recurrences.Results Of 99 patients who developed recurrences,28 developed early recurrence while 71 developed late recurrence.The patients with recurrences were treated with re-resection (n=33),percutaneous ethanol injection (PEI,n=7),radiofrequency ablation (RFA,n=10),transcatheter arterial chemoembolization (TACE,n =27),systemic chemotherapy (n=1),Chinese medicine (n=1),and conservative management (n=20).The re-resection rate was higher in the late than in the early recurrence group (P=0.04).In this study,reresection,PEI,and RFA were considered as curative therapies.There was no significant difference in the overall survival (OS) for patients who received these different curative therapeutic procedures (P=0.68).The 1,3-,and 5-year OS of patients with recurrences who were treated with curative treatment were comparable to those patients who did not develop recurrences (100%,86.0%,63.5% vs 85.2%,72.2%,64.3%,P=0.71).The 1-,3-,and 5-year OS of patients who received TACE for recurrences were 100%,66.7%,and 44.4% respectively.The results were poorer than patients who received curative treatment for recurrences (P=0.03),but were better than those who received conservative management after recurrences (80.0 %,25.0 %,and 10.0 %,P< 0.01).Conclusions Reresection,PEI and RFA are optimal curative methods for recurrent PCCCL.TACE plays an important role in the management of patients with recurrent PCCCL who cannot be treated with curative methods.